𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-hodgkin's lymphoma

✍ Scribed by Reena Nair; Gopal Ramakrishnan; Narendran N. Nair; Tapan K. Saikia; Purvish M. Parikh; Sandhaya R. Joshi; Chitralekha S. Soman; Maryann Mukhadan; Ketayun T. Dinshaw; Suresh H. Advani

Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
86 KB
Volume
82
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

Combination chemotherapy consisting of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, and bleomycin (MACOP-B) has been frequently used for the treatment of non-Hodgkin's lymphoma. This randomized study was undertaken to assess the efficacy and toxicity of this regimen when either doxorubicin or epirubicin was used as the anthracycline drug.

METHODS.

Between April 1989 and December 1993, 211 previously untreated patients with intermediate grade and high grade non-Hodgkin's lymphoma were randomized to receive either doxorubicin (n Ο­ 106) or epirubicin (n Ο­ 105) with the MACOP-B regimen. These patients were followed through December 1996.

Numerous clinical features predictive of response and survival were analyzed.

Cardiac and noncardiac toxicity in the two treatment arms were compared.

πŸ“œ SIMILAR VOLUMES

The incidence of lymphoma in first-degre
The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma : Results and limitations of a registry-linked study
✍ Ora Paltiel; Tal Schmit; Bella Adler; Eliezer A. Rachmilevitz; Aaron Polliack; A πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 104 KB πŸ‘ 1 views

## Background: The precise incidence of familial hodgkin disease (hd) and non-hodgkin lymphoma (nhl) in first-degree relatives is unknown. through record linkage using two population-based sources, the authors estimated the risk of hd and nhl in family members of lymphoma probands. ## Methods: Th

CEOP treatment results and validity of t
CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma
✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 125 KB

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa

Treatment of non-Hodgkin's lymphoma in t
Treatment of non-Hodgkin's lymphoma in the elderly: an update
✍ Umberto Tirelli; Vittorina Zagonel; Domenico Errante; Lucia Fratino; Silvio Monf πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 166 KB πŸ‘ 1 views

Recent studies specifically directed toward assessing the outcome of older patients with non-Hodgkin's lymphoma (NHL) indicate that age per se is an important and independent prognostic factor for response and survival. We report a review of the clinical trials of the literature and the Aviano Group

A randomized Phase III trial of etoposid
A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma
✍ Fikri Δ°Γ§li; Δ°smail Γ‡elik; Faruk Aykan; AytuΗ§ Üner; Ahmet Demirkazik; Ahmet Γ–zet; πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

## BACKGROUND. Gastric carcinoma is a substantial health problem in Turkey, and the majority of patients present with inoperable disease. The aim of this randomized trial was to assess the activity of 5-fluorouracil versus etoposide when combined with epirubicin plus cisplatin in patients with adv